Delivering a pharmacogenetic service: Is there a role for genetic counselors?

Journal of Genetic Counseling

Volumn 21, Issue 4, 2012, Pages 527-535

  Callard, Alice ^a,b   Newman, William ^a   Payne, Katherine ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b PRINCESS ANNE HOSPITAL   (United Kingdom)

Author keywords

Genetic counselors; Pharmacogenetics; Qualitative; Role; Views

Indexed keywords

ARTICLE; FEMALE; GENETIC COUNSELING; HUMAN; INTERVIEW; MALE; MANPOWER; PHARMACOGENETICS; PROFESSIONAL STANDARD;

FEMALE; GENETIC COUNSELING; HUMANS; INTERVIEWS AS TOPIC; MALE; PHARMACOGENETICS; PROFESSIONAL ROLE;

EID: 84863628022     PISSN: 10597700     EISSN: 15733599     Source Type: Journal    
DOI: 10.1007/s10897-011-9415-4     Document Type: Article

References (46)

1. Ashley, E. A., Butte, A. J., Wheeler, M. T., Chen, R., Klein, T. E., Dewey, F. E., et al. (2010). Clinical assessment incorporating a personal genome. Lancet, 375, 1525-1535.
2. Bowling, A. (2002). Research Methods in Health: Investigating health and health services (2nd ed.). Maidenhead: Open University Press.
3. Bagos, P. G., Elefsinioti, A. L., Nikolopoulos, G. K., & Hamodrakas, S. J. (2007). The GNB3 C825T polymorphism and essential hypertension: a meta-analysis of 34 studies including 14, 094 cases and 17, 760 controls. Journal of Hypertension, 25, 487-500. (Pubitemid 46213782)
4. Becquemont, L., Alfirevic, A., Amstutz, U., Brauch, H., Jacqz-Aigrain, E., Laurent-Puig, P., et al. (2011). Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB Conference on Pharmacogenetics and Pharmacogenomics. Pharmacogenomics, 12(1), 113-124.
5. Buchanan, A., Califano, A., Kahn, J., McPherson, E., Robertson, J., & Brody, B. (2002). Pharmacogenetics: ethical issues and policy options. Kennedy Institute of Ethics Journal, 2, 1-15.
6. Caldwell, J. (2001). The pharmacogenetic basis of adverse drug reactions. International Journal of Pharmaceutical Medicine, 15, 83-84. (Pubitemid 32417561)
7. Clemerson, J. P., Payne, K., Bissell, P., & Anderson, C. (2006). Pharmacogenetics, the next challenge for pharmacy? Pharmacy World & Science, 28, 126-130. (Pubitemid 44584044)
8. Consortium on Pharmacogenetics (2002) Pharmacogenetics: Ethical and regulatory issues in research and clinical practice. Report of the Consortium on Pharmacogenetics Findings and Recommendations, 1-43.
9. Department of Health White Paper (2003). Our inheritance, our future. Realising the potential of genetics in the NHS. Presented to Parliament by the Secretary of State for Health by Command of Her Majesty, The Stationery Office, Norwich, 1-99.
10. Donnai, D. (2002). Genetic services. Clinical Genetics, 61, 1-6. (Pubitemid 36372594)
11. Eccles, D. M., Evans, D. G., & Mackay, J. (2000). Guidelines for a genetic risk based approach to advising women with a family history of breast cancer. UK Cancer Family Study Group (UKCFSG). Journal of Medical Genetics, 37(3), 203-209. (Pubitemid 30245915)
12. Ellingrod, V. L., & Moline, J. (2007). Incorporating pharmacogenomics into practice. Journal of Pharmacy Practice, 20(3), 277-282.
13. Evans, W. E., & McLeod, H. L. (2003). Pharmacogenomics: drug disposition, drug targets and side effects. The New England Journal of Medicine, 348(6), 538-549. (Pubitemid 36159890)
14. Evans, W. E., & Relling, M. V. (1999). Pharmacogenomics: translating functional genomics into rational therapeutics. Science, 286, 487-491.
15. Evans, W. E., & Relling, V. (2004). Moving towards individualised medicine with pharmacogenomics. Nature, 429, 464-468. (Pubitemid 38715141)
16. Fargher, E. A., Tricker, K., Newman, W., Elliott, R., Roberts, S. A., Shaffer, J. L., et al. (2007). Current use of pharmacogenetic testing: a national survey of thiopurine methyltransferase testing prior to azathioprine prescription. Journal of Clinical Pharmacy and Therapeutics, 32, 187-195. (Pubitemid 46449703)
17. Fargher, E. A., Eddy, C., Newman, W., Qasim, F., Tricker, K., Elliott, R. A., et al. (2007). Patients' and healthcare professionals' views on pharmacogenetic testing and its future delivery in the NHS. Pharmacogenomics, 8(11), 1511-1519. (Pubitemid 350286396)
18. Finch, J. (1987). The vignette technique in survey research. Sociology, 21, 105-114.
19. Frueh, F. W., & Gurwitz, D. (2004). From pharmacogenetics to personalized medicine: a vital need for educating health professionals and the community. Pharmacogenomics, 5(5), 571-579. (Pubitemid 39023073)
20. Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., et al. (2009). Inhibition of poly (ADP-ribose) polymerase in tumors from BRCA mutation carriers. The New England Journal of Medicine, 361(2), 123-134.
21. Gardiner, S. J., & Begg, E. J. (2005). Pharmacogenetic testing for drug-metabolizing enzymes: is it happening in practice? Pharmacogenetics and Genomics, 15, 365-369. (Pubitemid 40676559)
22. Goetz, M. P., Kamal, A., & Ames, M. M. (2008). Tamoxifen pharmacogenetics: the role of CYP2D6 as a predictor of drug response. Clinical Pharmacology, Therapy, 83(1), 160-166.
23. Haga, S. B., & Burke, W. (2008). Pharmacogenetic testing: not as simple as it seems. Genetics in Medicine, 10(6), 391-395.
24. Hedgecoe, A. (2007). Education, ethics and knowledge deficits in clinical pharmacogenetics. Pharmacogenomics, 8(3), 267-270. (Pubitemid 46477737)
25. Higgs, J., Gambhir, N., Ramsden, S. C., Poulton, K., & Newman, W. G. (2010). Pharmacogenetic testing in the United Kingdom genetics and immunogenetics laboratories. Genetic Testing and Molecular Biomarkers, 14(1), 121-125.
26. Hopkins, M. M., Ibarreta, D., Gaisser, S., Enzing, C. M., Ryan, J., Martin, P. A., et al. (2006). Putting pharmacogenetics into practice. Nature Biotechnology, 24(4), 403-410.
27. Kalow, W. (1956). Familial incidence of low pseudocholinesterase level. Lancet, 2, 576-577.
28. Kiani, J. G., Saeed, M., Parvez, S. H., & Frossard, P. M. (2005). Association of G-protein beta 3 subunit gene (GNB3) T825 allele with type II diabetes. Neuro Endocrinology Letters, 26, 87-88. (Pubitemid 40674208)
29. Kinmonth, A. L., Reinhard, J., Bobrow, M., & Pauker, S. (1998). Implications for clinical services in Britain and the United States. BMJ, 316(7133), 767-770. (Pubitemid 28121084)
30. Lash, T. J. (2010). Evidence and practice regarding the role for CYP2D6 inhibition in decisions about tamoxifen therapy. Journal of Clinical Oncology, 28(8), 1273-1275.
31. McLeod, H. L., & Silva, C. (2002). The thiopurine S-methyltransferase gene locus - implications for clinical pharma-cogenomics. Pharmacogenomics, 3, 89-98. (Pubitemid 34285242)
32. Melzer, D., Raven, A., Detmer, D. E., Ling, T. & Zimmern, R. L. (2003). My very own medicine: what must I know? Information policy of Pharmacogenetics Project. The Department of Public Health and Primary Care, University of Cambridge, 1-69.
33. Netzer, C., & Biller-Andorno, N. (2004). Pharmacogenetic testing, informed consent and the problem of secondary information. Bioethics, 18(4), 344-360. (Pubitemid 38988456)
34. O'Daniel, J. M. (2010). The prospect of genome-guided preventative medicine: a need and opportunity for genetic counselors. Journal of Genetic Counseling, 19, 315-327.
35. Ormond, K. E., Wheeler, M. T., Hudgins, L., Klein, T. E., Butte, A. J., Altman, R. B., et al. (2010). Challenges in the clinical application of whole-genome sequencing. Lancet, 375, 1749-1751.
36. Payne, K., Fargher, E. A., Roberts, S. A., Tricker, K., Elliott, R. A., Ratcliffe, J., et al. (2011). Valuing pharmacogenetic testing services: a comparison of patients' and healthcare professionals' preferences. Value in Health, 14(1), 121-134.
37. Pirmohamed, M., James, S., Meakin, S., Green, C., Scott, A. K., Walley, T. J., et al. (2004). Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ, 329(7456), 15-19. (Pubitemid 38869995)
38. Resta, R., Biesecker, B. B., Bennett, R. L., Blum, S., Hahn, S. E., Strecker, M. N., et al. (2006). A new definition of genetic counseling: National Society of Genetic Counselors' task force report. Journal of Genetic Counseling, 15(2), 77-83. (Pubitemid 43876101)
39. Robertson, J. A. (2001). Consent and privacy in pharmacogenetic testing. Nature Genetics, 28, 207-209. (Pubitemid 32626017)
40. Rogausch, A., Prause, S., Schallenberg, A., Brockmoller, J., & Himmel, W. (2006). Patients' and physicians' perspectives on pharmacogenetic testing. Pharmacogenomics, 7(1), 49-59.
41. Shah, J. (2004). Criteria influencing the clinical uptake of pharmaco-genomic strategies. BMJ, 328, 1482-1486. (Pubitemid 38829912)
42. Shields, A. E., Blumenthal, D., Weiss, K. B., Comstock, C. B., Currivan, D., & Lerman, C. (2005). Barriers to translating emerging genetic research on smoking into clinical practice. Perspectives of primary care physicians. Journal of General Internal Medicine, 20(2), 131-138. (Pubitemid 40626990)
43. Strauss, A., & Corbin, J. (1990). Basics of qualitative research: Grounded theory procedures and techniques (2nd ed.). London: Sage.
44. Weinshilboum, R. (2003). Inheritance and drug response. The New England Journal of Medicine, 348, 529-537. (Pubitemid 36159889)
45. Weinshilboum, R., & Wang, L. (2004). Pharmacogenomics: Bench to bedside. Nature Reviews. Drug Discovery, 3(9), 739-748. (Pubitemid 39242826)
46. Wilkie, M. J., Smith, D., Reid, I. C., Day, R. K., Matthews, K., Wolf, C. R., et al. (2007). A splice site polymorphism in the G-protein beta subunit influences antidepressant efficacy in depression. Pharmacogenetics and Genomics, 17, 207-215. (Pubitemid 46668005)